Taisho said to near US$1.6 billion deal for Bristol-Myers's UPSA: Bloomberg


Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd is said to be close to a US$1.6 billion deal for Bristol-Myers Squibb Co's French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter. Employees work on paracetamol production line for UPSA brand of Bristol-Myers Squibb Group at the company's factory in Le Passage, near Agen, France March 29, 2018.



from Biotech News